HURA

TuHURA Biosciences, Inc./NV

4 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 29

Secured $50 million revolving credit facility to fund operations.

capital raise

70%

neutralMay 29

Established a long-term debt obligation with a related-party affiliate.

debt restructure

50%

bullishMay 15

Secured $50M revolving credit facility and $7M from registered direct offering.

capital raise

70%

bearishMay 15

Reported a net loss of $7.5M for the quarter with widening operating expenses.

earnings miss

60%

neutralMay 15

New credit facility provides runway but introduces high interest and profit-sharing obligations.

debt restructure

50%

bullishMay 15

Secured $50M revolving credit facility and $7M from registered direct offering.

capital raise

70%

bearishMay 15

Reported a net loss of $7.5M for the quarter with widening operating expenses.

earnings miss

60%

neutralMay 15

New credit facility provides runway but introduces high interest and profit-sharing obligations.

debt restructure

50%

neutralMar 31

Secured over $27 million through PIPE, RDO, and ATM facilities to extend runway into Q3 2026.

capital raise

60%

bullishMar 31

Acquired Kineta, Inc., adding the TBS-2025 VISTA-inhibitor to the oncology pipeline.

acquisition

70%

bearishMar 31

Operating cash used increased 88% YoY, reflecting accelerating clinical burn.

margin compression

80%

bullishMar 31

Obtained a binding FDA Special Protocol Assessment for the lead product's Phase 3 trial.

regulatory action

90%

Filing History

8-KMay 29, 2026

The recent 8-K filing confirms that TuHURA Biosciences has begun utilizing a $50 million revolving credit facility to support general corporate purposes. While the availability of non-dilutive capital is a positive signal for short-term runway, the related-party nature of the lender creates a complex risk-reward profile for investors. The market's reaction will likely depend on whether the company can leverage this liquidity to achieve clinical success before the debt obligations or potential covenant breaches become a primary driver of the company's financial health.

10-QMay 15, 2026

The Q1 2026 filing paints a picture of a biotech company at a crossroads of extreme leverage and high clinical potential. The primary tension for investors lies in whether the $50 million credit facility is a lifeline or a trap. While it provides the necessary oxygen to reach the 2027 Phase 3 data readout, it does so by mortgaging the company's future profits and granting a first-priority lien on all assets to a concentrated shareholder. Ultimately, the investment thesis has shifted from a question of 'can they survive' to 'can they execute.' The clinical success of IFx-2.0 is now the only viable path to solvency, as the company's debt obligations and cash burn make a break-even scenario impossible. Investors must weigh the potential for a binary valuation surge in 2027 against the very real risk of a liquidity crunch or a debt-driven restructuring if clinical milestones are missed.

10-KMar 31, 2026

The 10-K filing presents a classic biotech trade-off: high-conviction scientific innovation versus acute financial instability. On one hand, TuHURA possesses a sophisticated platform and a regulatory-approved trial design that could unlock a massive market for patients resistant to current immunotherapies. The leadership's track record of multi-billion dollar exits provides a layer of execution credibility that is often missing in early-stage biotech. However, the financial data indicates a company operating on a razor's edge. The gap between the current cash position and the 2027 data readout is vast, implying that the 'runway' is essentially a series of anticipated capital raises. For investors, the filing transforms the investment from a pure bet on science into a bet on the company's ability to continuously secure funding without completely erasing existing shareholder value through dilution.